Response Genetics, Inc. Announces Contract With Blue Cross and Blue Shield of Illinois
July 08, 2013 07:00 ET
|
Response Genetics, Inc.
LOS ANGELES, July 8, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
Response Genetics Achieves Milestone Payments Totaling $1,000,000 for Services Provided to GlaxoSmithKline in the Development of BRAF-Inhibitor Tafinlar(R) (dabrafenib)
June 04, 2013 07:00 ET
|
Response Genetics, Inc.
LOS ANGELES, June 4, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology 2013 Annual Meeting
May 20, 2013 07:00 ET
|
Response Genetics, Inc.
LOS ANGELES, May 20, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
Response Genetics, Inc. Announces Contract With Blue Shield of California
May 16, 2013 07:00 ET
|
Response Genetics, Inc.
LOS ANGELES, May 16, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's...
Response Genetics, Inc. Announces First Quarter 2013 Financial Results
May 14, 2013 07:00 ET
|
Response Genetics, Inc.
Q1 Revenue Increases Over 40% to $5.6 Million Relative to Q1 2012 and Gross Margin Increases to 55%
First Quarter Losses decrease to $0.8 million relative to Q1 2012 loss of $3.1 million
LOS...
Response Genetics to Present at the 2013 UBS Global Healthcare Conference
May 08, 2013 07:00 ET
|
Response Genetics, Inc.
LOS ANGELES, May 8, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response...
Response Genetics, Inc. to Release First Quarter 2013 Financial Results and Host Conference Call on May 14, 2013
May 06, 2013 07:00 ET
|
Response Genetics, Inc.
LOS ANGELES, May 6, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response...
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
March 21, 2013 07:00 ET
|
Response Genetics, Inc.
--- Q4 Revenue Increases 11% to $5.5 Million Relative to Q4 2011 and Gross Margin Increases to 54% ---
--- Fourth Quarter Losses Decrease to $0.5 Million Relative to Q4 2011 Loss of $3.9 Million...
Response Genetics to Present at the 25th Annual ROTH Conference
March 12, 2013 07:00 ET
|
Response Genetics, Inc.
LOS ANGELES, March 12, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today that...
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on March 21, 2013
March 07, 2013 07:00 ET
|
Response Genetics, Inc.
LOS ANGELES, March 7, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, will announce...